If you have this disease, please follow your doctor's complete medical plan; Before using the multidisciplinary rehabilitation program, you must consult the attending doctor. If your attending doctor does not recommend you to join the supplement conditioning combination, please do not use it. If you need to seek a second consultation from another doctor, you can contact our online doctor without borders. Or another professional doctor in your own city.
Nonalcoholic fatty liver
Nonalcoholic fatty liver disease (NAFLD) is a term for a series of diseases caused by liver fat accumulation. This is usually seen in overweight or obese people.
A healthy liver should contain little or no fat. It is estimated that one in three people in the UK has NAFLD in the early stage, and the liver contains a small amount of fat.
Early NAFLD usually does not cause any harm, but if the condition worsens, it may lead to serious liver damage, including cirrhosis.
High levels of liver fat also increase the risk of serious health problems, such as diabetes, hypertension and kidney disease.
If you already have diabetes, NAFLD wll increase your chances of heart disease. If detected and treated early, it is possible to block the deterioration of NAFLD and reduce the amount of fat in the liver. (1)
The main phases of NAFLD are:
Simple fatty liver (steatosis) - a basically harmless accumulation of fat in hepatocytes that can only be diagnosed by testing for other reasons
Nonalcoholic steatohepatitis (NASH) - a more severe NAFLD with inflammation of the liver; It is estimated that this will affect up to 5% of the UK population
Fibrosis - persistent inflammation leads to scar tissue around and near the liver, but the liver still works normally
Cirrhosis - the most severe stage, occurs after years of inflammation, liver atrophy, scarring and caking; This damage is permanent and can lead to liver failure (the liver stops working normally) and liver cancer
The development of fibrosis or cirrhosis may take years. It is important to change your lifestyle to prevent the disease from getting worse.
Do I have the risk of nonalcoholic fatty liver disease (NAFLD)?
Obese or overweight - especially if you have a lot of fat around your waist (apple shaped body)
Type 2 diabetes mellitus
high blood pressure
Metabolic syndrome (diabetes, hypertension and obesity syndrome)
They are all over 50
However, NAFLD is diagnosed in people without any of these risk factors, including young children.
Although very similar to alcohol-related liver disease (arld), NAFLD is not caused by excessive drinking.
Symptoms of nonalcoholic fatty liver disease (NAFLD)
NAFLD usually has no symptoms in the early stage. You may not know you have the disease unless you are diagnosed in a test for other reasons.
Occasionally, patients with nonalcoholic steatohepatitis or fibrosis (more advanced stage of NAFLD) may experience:
Faint or pain in the upper right of the abdomen (lower right of the ribs)
Unexplained weight loss
If cirrhosis (the most advanced stage) develops, you may develop more serious symptoms, such as:
Yellowing of skin and eyes (jaundice)
Swelling (edema) in the legs, ankles, feet or abdomen.
Key research results:
Reducing liver lipid level: it has been proved that the destruction of liver lipid metabolism is the most likely cause of early FLD. Taurine plays a role in reducing liver steatosis by reducing triglyceride (TG) and cholesterol levels (2)
Nonalcoholic fatty liver: bile acid signal is closely related to biological disorders and nonalcoholic fatty liver. In the past decade, stimulating bile acid receptors with its agonists has been widely used in the treatment of nonalcoholic fatty liver in animal models and clinical trials. Early evidence indicates the potential of bile acid receptor agonists in the treatment of nonalcoholic fatty liver, but its long-term safety and efficacy need to be further clarified. (3)
Cholangitis: a multicenter, randomized, double-blind trial to compare the efficacy and safety of TUDCA and UDCA in Chinese patients with primary cholangitis (4)
Liver enzyme and blood lipid: the level of serum liver enzyme decreased significantly (P < 0.001). Aspartate aminotransferase, alanine aminotransferase and γ- The average level of glutamyl aminotransferase decreased by 29.7% ± 14.5%, 24.1 ± 15.9% and 26.6% ± 19.9% after one month of treatment, and increased by 5% ~ 10% after three months of treatment. The level of total bilirubin also improved slightly. (9)
Liver cirrhosis: the treatment of liver cirrhosis is safe and effective, especially better than UDCA in improving biochemical expression. However, both drugs had no effect on serum markers of liver fibrosis at 6 months of treatment. (5)
Biliary polyps: lesions were detected in 12 patients: 8 cases were single and fixed lesions; 2 cases had multiple and fixed lesions; 2 cases had multiple pedicled lesions. The lesion size ranged from 4 mm to 18 mm. Of the 12 cases, the polyps disappeared completely in 8 cases after 6 months and in 1 case after 3 months. Polyps dissolve regardless of their size and location. (6)
Hypercholesterolemia: Hypercholesterolemia occurs in 64% of patients with cholelithiasis and 56% of patients with gallbladder cholesterol disease. 68% of patients with cholelithiasis and 69% of patients with gallbladder cholesterol disease have a slow increase in total cholesterol levels (in the range of 5.3-6.1 mmol / L), and hypercholesterolemia rarely occurs, and does not exceed 2-4%. In 45% of patients with cholelithiasis and 49% of patients with gallbladder cholesterol disease, hypercholesterolemia disappeared after 3 months of ursulose treatment. (7)
Calcium bilirubin stone: dissolution and disintegration of calcium bilirubin stone objective to investigate the effect of stone dissolving agent in human bile and its effect on bile duct irrigation in dogs. (10)
Psoriasis: Hungarian study: oral bile acid supplementation for psoriasis for 1 to 6 weeks, coupled with a diet rich in vegetables and fruits, free of hot spices, alcohol, raw onions, garlic and carbonated soft drinks, 78.8% of patients' symptoms were relieved, while only 24.9% of patients receiving routine treatment recovered during treatment. Cholic acid effect is more obvious in acute psoriasis; 95.1% of the patients were asymptomatic. After 2 years, 57.9% were asymptomatic, while 6.0% were treated with routine treatment. (8)
Tang R. et al. (2019) Preventive or Curative Administration of Taurine Regulates Lipid Metabolism in the Liver of Rats with Alcoholic Liver Disease. In: Hu J., Piao F., Schaffer S., El Idrissi A., Wu JY. (eds) Taurine 11. Advances in Experimental Medicine and Biology, vol 1155. Springer, Singapore. https://doi.org/10.1007/978-981-13-8023-5_11
Caihua Wang,1 Chunpeng Zhu,1 Liming Shao,1 Jun Ye,1 Yimin Shen,2 and Yuezhong Ren. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. Volume 2019 |Article ID 7659509 | https://doi.org/10.1155/2019/7659509
Pan XL, Zhao L, Li L, Li AH, Ye J, Yang L, Xu KS, Hou XH. Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial. J Huazhong Univ Sci Technolog Med Sci. 2013 Apr;33(2):189-194. doi: 10.1007/s11596-013-1095-x. Epub 2013 Apr 17. PMID: 23592128.
G. Del Favero, F. Di Mario, T. Meggiato, P. Scalon, F.A. Bulzacchi, F. Mangano, G. Ricciardi, F. Battocchio, A. Caroli, Disappearance of gallbladder wall lesions after oral bile acids treatment—A pilot study, Current Therapeutic Research, Volume 54, Issue 4, 1993, Pages 384-388, ISSN 0011-393X, https://doi.org/10.1016/S0011-393X(05)80640-X.
Il'chenko AA, Drozhzhina IuV. [Effect of ursodeoxycholic acid on the characteristics of lipid metabolism in cholelithiasis and gall-bladder cholesterosis]. Eksp Klin Gastroenterol. 2007;(5):29-34, 164. Russian. PMID: 18389594.
Joseph E. Pizzorno, Michael T. Murray, Herb Joiner-Bey,69 - Psoriasis,
Mario Angelico, Costanzo Del Vecchio, Alessandro Nistri,Effect of tauroursodeoxycholic acid on serum liver enzyme and serum lipid levels in patients with chronic active hepatitis,Current Therapeutic Research,Volume 56, Issue 6,1995,Pages 626-634,ISSN 0011-393X,https://doi.org/10.1016/0011-393X(95)85055-4.
YOSHIHIRO TAKASAWA, NORIYOSHI SUZUKI, WATARU TAKAHASHI and TOSHIO SATO. A Study on the Dissolution and Disintegration of Calcium Bilirubinate Stones, with Special Reference to Effects of Litholytic Agents in Human Bile and to Irrigation of Bile Duct in Dogs. Tohoku J. exp. Med., 1982, 138, 383-395.
Editor(s): Joseph E. Pizzorno, Michael T. Murray, Herb Joiner-Bey,The Clinician's Handbook of Natural Medicine (Third Edition),Churchill Livingstone,2016,Pages 864-874,ISBN 9780702055140 https://doi.org/10.1016/B978-0-7020-5514-0.00078-6.